Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Invested Capital (2019 - 2025)

Vivos Therapeutics has reported Invested Capital over the past 7 years, most recently at -$1.3 million for Q4 2025.

  • Quarterly Invested Capital fell 116.62% to -$1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.3 million through Dec 2025, down 116.62% year-over-year, with the annual reading at -$1.3 million for FY2025, 116.62% down from the prior year.
  • Invested Capital was -$1.3 million for Q4 2025 at Vivos Therapeutics, down from $2.9 million in the prior quarter.
  • Over five years, Invested Capital peaked at $37.7 million in Q2 2021 and troughed at -$1.3 million in Q4 2025.
  • The 5-year median for Invested Capital is $6.7 million (2023), against an average of $10.4 million.
  • Year-over-year, Invested Capital soared 16563.04% in 2024 and then crashed 116.62% in 2025.
  • A 5-year view of Invested Capital shows it stood at $26.8 million in 2021, then plummeted by 82.09% to $4.8 million in 2022, then tumbled by 91.44% to $411000.0 in 2023, then soared by 1835.28% to $8.0 million in 2024, then crashed by 116.62% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Invested Capital are -$1.3 million (Q4 2025), $2.9 million (Q3 2025), and $4.7 million (Q2 2025).